Archived articles

Arturo casadevall

COVID-19 treatment

Drop in convalescent plasma use linked to excess deaths

Published June 16, 2021

Study suggests the declining use of the COVID-19 therapy at U.S. hospitals from November 2020 to February 2021 may have led to more than 29,000 excess COVID-19 deaths

Commentary

A 'healthy debate' on convalescent plasma

Published Sept 24, 2020

Hopkins immunologist Arturo Casadevall explains the different federal responses to the COVID-19 treatment and why it's normal to lack consensus in science / The Wall Street Journal

COVID-19

Hopkins gets $35M for blood plasma clinical trials

Published July 30, 2020

Two nationwide clinical trials will test the effectiveness of an outpatient treatment that may help COVID-19 patients' immune systems fight the virus

Collage of Arturo Casadevall holding a test tube

COVID-19

Convalescent plasma: A COVID-19 treatment speeds to clinical trials

Published July 28, 2020

An old-school approach offers a fast, stopgap solution for a modern pandemic

Illustration of coronavirus, blood cells, and plasma

Treating COVID-19

A fast-tracked therapy shows promise

Published April 8, 2020

Arturo Casadevall and his team have worked around the clock to develop a convalescent serum therapy using blood plasma from recovered patients

Treating COVID-19

Hopkins gets FDA approval to test blood plasma therapy

Published April 3, 2020

The treatment uses the blood sera from recovered COVID-19 patients to treat those who are critically ill or to boost immunity for those at high risk of contracting the disease

Coronavirus

Hopkins-led COVID-19 treatment research receives funding

Published March 27, 2020

Public-private initiative including Bloomberg Philanthropies, state of Maryland will provide $4M to a JHU-led research team exploring therapeutic uses of blood plasma from recovered COVID-19 patients